GlassScriptPhysician profile
David P Yamini
NPI 1780849034
$12,749.36
in general payments reported to CMS, 2019-2025
40 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $2,751 · 2021: $4,166 · 2022: $1,081 · 2023: $963 · 2024: $1,453 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,685 · Gift: $245 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,685.11 |
| Gift | $245.43 |
| Education | $154.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $6,199.08 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,190.40 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Janssen Biotech, INC. | $1,076.76 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $428.48 | 2021-2025 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $424.59 | 2020-2025 | Suflave, Sutab |
| Capsovision, INC. | $416.65 | 2025 | Capsocam Plus |
| Regeneron Healthcare Solutions, INC. | $367.01 | 2022-2025 | Dupixent |
| Abbvie INC. | $347.50 | 2020-2025 | Linzess, Viberzi |
| Merck Sharp & Dohme LLC | $261.69 | 2019-2024 | Dificid, Gardasil 9, Gardasil |
| Qol Medical, LLC | $227.92 | 2020-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $155.53 | 2025 | Ibsrela |
| Concordia Pharmaceuticals INC. | $155.53 | 2019 | |
| Intercept Pharmaceuticals, INC. | $124.89 | 2019 | |
| Romark Laboratories, Lc | $119.97 | 2019-2020 | |
| Genzyme Corporation | $117.93 | 2022-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yamini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.